Your browser doesn't support javascript.
loading
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment.
Miller, Carly D; Likasitwatanakul, Pornlada; Toye, Eamon; Hwang, Justin H; Antonarakis, Emmanuel S.
Afiliación
  • Miller CD; Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
  • Likasitwatanakul P; Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
  • Toye E; Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Hwang JH; Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
  • Antonarakis ES; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Expert Rev Anticancer Ther ; : 1-16, 2024 Sep 20.
Article en En | MEDLINE | ID: mdl-39275993
ABSTRACT

INTRODUCTION:

Prostate cancer continues to be a major cause of morbidity and mortality for men worldwide. Enzalutamide, a second-generation non-steroidal antiandrogen that blocks androgen receptor (AR) transcriptional activity, is a treatment for biochemically recurrent, metastatic, castration-sensitive, and castration-resistant tumors. Unfortunately, most patients ultimately develop resistance to enzalutamide, making long-term treatment with this agent challenging. AREAS COVERED We performed a literature search of PubMed without date restrictions to investigate the literature surrounding enzalutamide and discuss the current uses of enzalutamide, proposed mechanisms driving resistance, and summarize current efforts to mitigate this resistance. EXPERT OPINION Enzalutamide is an effective prostate cancer therapy that is currently used in biochemically recurrent and metastatic disease and for both castration-sensitive and castration-resistant tumors. Unfortunately, resistance to enzalutamide occurs in each of these scenarios. In the clinical setting, enzalutamide-resistant tumors are either AR-driven or AR-indifferent. AR-dependent resistance mechanisms include genomic or epigenomic events that result in enhanced AR signaling. Tumors that do not require AR signaling instead may depend on alternative oncogenic pathways. There are numerous strategies to mitigate enzalutamide resistance, including concurrent use of PARP inhibitors or immune therapies. Additional work is required to uncover novel approaches to treat patients in the enzalutamide-resistant setting.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Expert Rev Anticancer Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Expert Rev Anticancer Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido